- Home
- EXFY vs SLRN Comparison
EXFY vs SLRN Comparison
Compare EXFY & SLRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- SLRN
- Stock Information
- Founded
- EXFY 2008
- SLRN 2020
- Country
- EXFY United States
- SLRN United States
- Employees
- EXFY N/A
- SLRN N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- SLRN Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- SLRN Health Care
- Exchange
- EXFY Nasdaq
- SLRN Nasdaq
- Market Cap
- EXFY 253.2M
- SLRN 224.6M
- IPO Year
- EXFY 2021
- SLRN 2023
- Fundamental
- Price
- EXFY $2.38
- SLRN $2.36
- Analyst Decision
- EXFY Buy
- SLRN Hold
- Analyst Count
- EXFY 4
- SLRN 5
- Target Price
- EXFY $4.75
- SLRN $9.60
- AVG Volume (30 Days)
- EXFY 336.9K
- SLRN 703.6K
- Earning Date
- EXFY 05-08-2025
- SLRN 05-16-2025
- Dividend Yield
- EXFY N/A
- SLRN N/A
- EPS Growth
- EXFY N/A
- SLRN N/A
- EPS
- EXFY N/A
- SLRN N/A
- Revenue
- EXFY $141,775,000.00
- SLRN N/A
- Revenue This Year
- EXFY $9.56
- SLRN $267.11
- Revenue Next Year
- EXFY $6.86
- SLRN N/A
- P/E Ratio
- EXFY N/A
- SLRN N/A
- Revenue Growth
- EXFY N/A
- SLRN N/A
- 52 Week Low
- EXFY $1.24
- SLRN $1.85
- 52 Week High
- EXFY $4.13
- SLRN $7.25
- Technical
- Relative Strength Index (RSI)
- EXFY 33.37
- SLRN 47.93
- Support Level
- EXFY $2.78
- SLRN $2.34
- Resistance Level
- EXFY $3.06
- SLRN $2.64
- Average True Range (ATR)
- EXFY 0.16
- SLRN 0.17
- MACD
- EXFY -0.01
- SLRN 0.02
- Stochastic Oscillator
- EXFY 24.44
- SLRN 48.70
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
About SLRN ACELYRIN INC.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.